Pfizer Inc. said it asked European Union regulators to approve its drug candidate axitinib as a treatment for advanced renal cell carcinoma in patients who haven't been helped by other therapies.
The FDA has approved Optimer Pharmaceuticals' antibacterial drug DIFICID (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea in adults.
Mymetics Corporation reports its HIV-1 (Human Immunodeficiency Virus type 1) vaccine proved to be safe, well-tolerated, and demonstrated a high level of immunogenicity in a Phase I trial of 24 healthy women.
Mice and humans share about 95% of their genes, and mice are recognized as the leading experimental model for studying human biology and disease.
The U.S. Food and Drug Administration (FDA) approved TEVA’s Abbreviated New Drug Application (ANDA) to market a generic version of ViiV Healthcare Company’s HIV treatment, Combivir Tablets (Lamivudine and Zidovudine).
InSite Vision Incorporated reported it will join Merck and Pfizer Inc. in filing a patent infringement lawsuit against Sandoz Inc.
Aegerion Pharmaceuticals Inc. presented further late-stage study data for its drug candidate lomitapide on May 31, saying the drug is safe for lowering "bad" cholesterol and patients who continued to use it for more than a year maintained reductions.
Excelimmune, Inc. announced that it will use the proceeds of $10.5 million in Series B financing to advance Staphguard, a human recombinant polyclonal antibody (HRPA) candidate against methicillin-resistant Staphylococcus aureus (MRSA), toward the clinic and improve the company’s discovery platform and proof-of-principle for its manufacturing systems.
In a new study, researchers describe a chemical interaction between a clotting factor and a cell membrane that has baffled scientists for decades.
Thermo Fisher Scientific Inc. introduced a downloadable software protocol library for its Multiskan GO microplate spectrophotometer. There are currently 20 ready-made protocols available to cover a wide variety of photometric applications.
Integrated DNA Technologies offers a comprehensive range of customizable products for RNA interference applications. The Screening Dicer-substrate siRNA provides researchers with a cost-effective and quick solution for their RNAi requirements.
Researchers have pinpointed a small RNA that spurs cells to manufacture a particular splice variant of a key neuronal protein, potentially promoting Alzheimer's disease or other types of neurodegeneration.
Sage-N Research, Inc. announced that the State University of New York at Buffalo’s pharmaceutical sciences research group has chosen the SORCERER platform to assist with its advanced proteomics research.
Despite showing promising results in a recent phase 2 trial, administration of a novel gene therapy to enhance the growth of new blood vessels in people with critical limb ischaemia, does not reduce amputation or death.